Terms: = Ovarian cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2
701 results:
1. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
2. Complexity of the Genetic Background of Oncogenesis in ovarian cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract] [Full Text] [Related]
3. Genome-wide quantification of copy-number aberration impact on gene expression in ovarian high-grade serous carcinoma.
Jamalzadeh S; Dai J; Lavikka K; Li Y; Jiang J; Huhtinen K; Virtanen A; Oikkonen J; Hietanen S; Hynninen J; Vähärautio A; Häkkinen A; Hautaniemi S
BMC Cancer; 2024 Feb; 24(1):173. PubMed ID: 38317080
[TBL] [Abstract] [Full Text] [Related]
4. Somatic Genomic and Transcriptomic Characterization of Primary ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
[TBL] [Abstract] [Full Text] [Related]
5. DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in kras-driven pancreatic and ovarian carcinomas.
Bildik G; Gray JP; Mao W; Yang H; Ozyurt R; Orellana VR; De Wever O; Carey MS; Bast RC; Lu Z
Autophagy; 2024 Mar; 20(3):675-691. PubMed ID: 38169324
[TBL] [Abstract] [Full Text] [Related]
6. ovarian Mesonephric-like Adenocarcinoma Recurring With a Rhabdomyosarcoma Component: A Case Report.
Yamamoto A; Nagai T; Sukeda A; Kajiwara M; Fukunaga M; Sasaki T; Kinoshita Y; Hayashi M; Hayashi S; Ono M; Futagami M; Nishi H
Int J Gynecol Pathol; 2024 May; 43(3):296-301. PubMed ID: 38085954
[TBL] [Abstract] [Full Text] [Related]
7. Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in ovarian cancer.
Heo J; Kim YN; Shin S; Lee K; Lee JH; Lee YJ; Choi Z; Park J; Min S; Kim SW; Choi JR; Kim S; Lee ST; Lee JY
Cancer Res; 2024 Feb; 84(3):468-478. PubMed ID: 38038965
[TBL] [Abstract] [Full Text] [Related]
8. Mucinous cystadenocarcinoma of the breast harbours TRPS1 expressions and PIK3CA alterations.
Chen WY; Hu YH; Tsai YH; Hang JF; Tan PH; Chen CJ
Histopathology; 2024 Feb; 84(3):550-555. PubMed ID: 37983855
[TBL] [Abstract] [Full Text] [Related]
9. Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers.
Biswas S; Mandal G; Anadon CM; Chaurio RA; Lopez-Bailon LU; Nagy MZ; Mine JA; Hänggi K; Sprenger KB; Innamarato P; Harro CM; Powers JJ; Johnson J; Fang B; Eysha M; Nan X; Li R; Perez BA; Curiel TJ; Yu X; Rodriguez PC; Conejo-Garcia JR
Immunity; 2023 Nov; 56(11):2570-2583.e6. PubMed ID: 37909039
[TBL] [Abstract] [Full Text] [Related]
10. Treatment of Recurrent Low-grade Serous ovarian cancer With MEK Inhibitors: A Systematic Review.
Kulkarni A; Cooke C; Fazelzad R; Fung-Kee-Fung M; May T; Zigras T
Am J Clin Oncol; 2024 Jan; 47(1):11-16. PubMed ID: 37823720
[TBL] [Abstract] [Full Text] [Related]
11.
Mulkidjan RS; Saitova ES; Preobrazhenskaya EV; Asadulaeva KA; Bubnov MG; Otradnova EA; Terina DM; Shulga SS; Martynenko DE; Semina MV; Belogubova EV; Tiurin VI; Amankwah PS; Martianov AS; Imyanitov EN
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686416
[TBL] [Abstract] [Full Text] [Related]
12. Mesonephric-like adenocarcinoma of the female genital tract: possible role of kras-targeted treatment-detailed molecular analysis of a case series and review of the literature for targetable somatic kras-mutations.
Brambs CE; Horn LC; Hiller R; Krücken I; Braun C; Christmann C; Monecke A; Höhn AK
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15727-15736. PubMed ID: 37668797
[TBL] [Abstract] [Full Text] [Related]
13. The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
Smith P; Bradley T; Gavarró LM; Goranova T; Ennis DP; Mirza HB; De Silva D; Piskorz AM; Sauer CM; Al-Khalidi S; Funingana IG; Reinius MAV; Giannone G; Lewsley LA; Stobo J; McQueen J; Bryson G; Eldridge M; ; Macintyre G; Markowetz F; Brenton JD; McNeish IA
Nat Commun; 2023 Jul; 14(1):4387. PubMed ID: 37474499
[TBL] [Abstract] [Full Text] [Related]
14. Long noncoding RNA LOC646029 functions as a ceRNA to suppress ovarian cancer progression through the miR-627-3p/SPRED1 axis.
Zhao P; Wang Y; Yu X; Nan Y; Liu S; Li B; Cui Z; Liu Z
Front Med; 2023 Oct; 17(5):924-938. PubMed ID: 37434064
[TBL] [Abstract] [Full Text] [Related]
15. Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience.
Kim YN; Chung YS; Lee JH; Park E; Lee ST; Kim S; Lee JY
J Gynecol Oncol; 2023 Nov; 34(6):e70. PubMed ID: 37417298
[TBL] [Abstract] [Full Text] [Related]
16. Ferroptosis-Mediated Cell Death Induced by NCX4040, The Non-Steroidal Nitric Oxide Donor, in Human Colorectal cancer Cells: Implications in Therapy.
Sinha BK; Bortner CD; Jarmusch AK; Tokar EJ; Murphy C; Wu X; Winter H; Cannon RE
Cells; 2023 Jun; 12(12):. PubMed ID: 37371096
[TBL] [Abstract] [Full Text] [Related]
17. The highs and lows of serous ovarian cancer.
Grisham RN; Manning-Geist BL; Chui MH
Cancer; 2023 Sep; 129(17):2613-2620. PubMed ID: 37366225
[TBL] [Abstract] [Full Text] [Related]
18. A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations.
Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Dvořák J; Němejcová K; Matěj R; Laco J; Drozenová J; Fabian P; Hausnerová J; Méhes G; Škapa P; Švajdler M; Cibula D; Frühauf F; Bártů MK; Dundr P
Diagn Pathol; 2023 Jun; 18(1):72. PubMed ID: 37303048
[TBL] [Abstract] [Full Text] [Related]
19. A prediction model to refine the timing of an early second-look laparoscopic exploration in patients with colon cancer at high risk of early peritoneal metastasis recurrence.
Fawaz J; Pocard M; Liberale G; Eveno C; Malgras B; Sideris L; Hübner M; Sabbagh C; Sgarbura O; Taibi A; Hobeika C
J Surg Oncol; 2023 Sep; 128(4):576-584. PubMed ID: 37226983
[TBL] [Abstract] [Full Text] [Related]
20. kras mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.
McHenry A; Rottmann DA; Buza N; Hui P
Virchows Arch; 2023 Jul; 483(1):71-79. PubMed ID: 37219599
[TBL] [Abstract] [Full Text] [Related]
[Next]
